COVID-19 mRNA vaccine candidate from Sanofi and Translate protects mice, monkeys: study

Moderna and Pfizer may be considered the front-runners in the effort to develop mRNA vaccines against COVID-19, but they’re not the only contenders in that race. Sanofi and its partner Translate Bio have also been working on a vaccine that uses mRNA to prompt an immune response—and now they have animal data that they believe provide strong backing for the phase 1/2 trial expected to start this quarter.